cyclacel - Robuta Search

https://www.fiercebiotech.com/biotech/cylcacel-back-peddles-phase-3-leukemia-drug-kicking-rights-over-daiichi Cyclacel passes phase 3 leukemia drug rights back to Daiichi Nov 10, 2022 - Despite making it as far as a phase 3 trial for acute myeloid leukemia as well as midstage studies for other cancers, the biotech has given up. phase 3 back to cyclacel passes leukemia https://finviz.com/news/47612/cyclacel-pharmaceuticals-inc-announces-execution-of-share-exchange-agreement-to-make-fitters-sdn-bhd-its-wholly-owned-subsidiary-to-accelerate-growth-and-stockholder-value CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN.... Stock screener for investors and traders, financial visualizations. cyclacel pharmaceuticals inc https://www.biospace.com/cyclacel-pharmaceuticals-reports-new-clinical-data-at-2024-asco-annual-meeting-highlighting-oral-fadraciclib-s-potential-as-a-precision-medicine-for-cancer Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral... Jun 3, 2024 - Cyclacel Pharmaceuticals, Inc. today announced that new clinical, pharmacokinetic (PK) and pharmacodynamic (PD) data from the CYC065-101 study of fadraciclib... https://www.fiercebiotech.com/biotech/investor-pumps-3m-cash-strapped-cyclacel-return-ceo-role Investor pumps $3M into Cyclacel in return for CEO role Jan 3, 2025 - David Lazar has come to the rescue of Cyclacel, pumping $3 million into the biotech as well as taking on the top role and shaking up the board. in return investor pumps 3m cyclacel https://www.globenewswire.com/news-release/2024/10/09/2960613/10564/en/Cyclacel-Pharmaceuticals-to-Present-New-Clinical-Data-From-Phase-2-Study-of-Oral-Fadraciclib-at-the-2024-EORTC-NCI-AACR-Symposium.html Cyclacel Pharmaceuticals to Present New Clinical Data From Initial safety and efficacy data from fadraciclib monotherapy in patients with advanced solid tumors preselected for CDKN2A and/or CDKN2B abnormalities ... clinical data cyclacel pharmaceuticals present new https://www.biospace.com/cyclacel-pharma-reports-first-quarter-2017-financial-results Cyclacel Pharma Reports First Quarter 2017 Financial Results - BioSpace first quarter financial results cyclacel pharma reports https://www.epo.org/de/boards-of-appeal/decisions/t092466eu1 T 2466/09 (Depsipeptide as immunosuppressant/ CYCLACEL) vom 20.08.2013 2466 09 depsipeptide https://www.biospace.com/press-releases/cyclacel-pharmaceuticals-inc-announces-execution-of-share-exchange-agreement-to-make-fitters-sdn-bhd-its-wholly-owned-subsidiary-to-accelerate-growth-and-stockholder-value CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN.... cyclacel pharmaceuticals inc https://www.biospace.com/cyclacel-pharmaceuticals-inc-announces-receipt-of-b-nasdaq-b-staff-determination-company-to-request-hearing Cyclacel Pharmaceuticals, Inc. Announces Receipt Of Nasdaq Staff Determination; Company To Request... cyclacel pharmaceuticals inc https://www.biospace.com/cyclacel-pharmaceuticals-inc-announces-pricing-of-public-offering-of-common-stock Cyclacel Pharmaceuticals, Inc. Announces Pricing Of Public Offering Of Common Stock - BioSpace cyclacel pharmaceuticals inc public offering common stock announces pricing https://www.biospace.com/cyclacel-pharmaceuticals-inc-reports-first-quarter-2015-financial-results Cyclacel Pharmaceuticals, Inc. Reports First Quarter 2015 Financial Results - BioSpace cyclacel pharmaceuticals inc first quarter financial results reports 2015 https://www.foxbusiness.com/markets/cyclacels-stock-plunges-after-disappointing-trial-results-of-its-cancer-treatment Cyclacel's Stock Plunges After Disappointing Trial Results Of Its Cancer Treatment | Fox Business Shares of Cyclacel Pharmaceuticals Inc. plunged 19% in premarket trade Thursday, after disappointing late-stage trial results of its leukemia treatment.